LIMX · Limitless X Holdings Inc. · Insider Trading

Reflects the issuance of shares of the issuer's common stock to EM1 Capital, LLC, a corporation, wholly-owned by the Reporting Person as consideration for the advancement of a $250,000 loan to the issuer.

Reflects the issuance of warrants to purchase 500,000 shares of the issuer's common stock, to EM1 Capital, LLC, as consideration for the advancement of a $250,000 loan to the issuer.

Reflects the issuance of shares of the issuer's common stock, pursuant to approval of the Board, in connection with the issuer entering into a promissory dated June 9, 2025, as amended, with the reporting person.

Reflects the issuance of shares of the issuer's common stock, pursuant to approval of the Board in connection with the issuer entering into a promissory note, dated June 11 2025, with the reporting person.

On April 14, 2025, the Issuer and Emblaze One, Inc. entered into a Debt Conversion Agreement, pursuant to which the Issuer and Emblaze One, Inc. agreed to convert $153,179 owed to Emblaze One, Inc. by the Issuer into 6,127 shares of the Issuer's Series D Preferred Stock, based on a conversion price of $25 per share.

The Reporting Person is the Chief Executive Officer of Emblaze One, Inc.

On April 14, 2025, Limitless X Holdings, Inc. (the "Issuer") and Jaspreet Mathur (the "Reporting Person") entered into a Debt Conversion Agreement, pursuant to which the Issuer and the Reporting Person agreed to convert $6,089,589 owed to the Reporting Person by the Issuer into 243,583 shares of the Issuer's Series D 15% Cumulative Redeemable Perpetual Preferred Stock ("Series D Preferred Stock"), based on a conversion price of $25 per share.

On April 14, 2025, the Issuer and EM1 Capital LLC entered into a Debt Conversion Agreement, pursuant to which the Issuer and EM1 Capital LLC agreed to convert $262,600 owed to EM1 Capital LLC by the Issuer into 10,504 shares of the Issuer's Series D Preferred Stock, based on a conversion price of $25 per share.

The Reporting Person is the Managing Member of EM1 Capital LLC.

Reflects the issuance of shares of the issuer's common stock in connection with the issuer entering into a promissory note, dated March 21, 2025, with the reporting person.

Reflects the issuance of shares of the issuer's Series D 15% Cumulative Redeemable Perpetual Preferred Stock in connection with the issuer entering into a promissory note, dated March 21, 2025, with the reporting person.

Reflects the grant of restricted shares of the issuer's common stock pursuant to the Limitless X Holdings Inc. 2022 Restricted Stock Plan.

Reflects the grant of restricted shares of the issuer's common stock pursuant to the Limitless X Holdings Inc. 2022 Restricted Stock Plan.

Reflects the grant of restricted shares of the issuer's common stock pursuant to the Limitless X Holdings Inc. 2022 Restricted Stock Plan.

Reflects the grant of restricted shares of the issuer's common stock pursuant to the Limitless X Holdings Inc. 2022 Restricted Stock Plan.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with her services rendered as a director of the issuer from May 20, 2022 through December 31, 2024.

On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.

Reflects the issuance of restricted shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person.

On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from May 20, 2022 through December 31, 2024.

On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from October 3, 2022 through December 31, 2024.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from May 20, 2022 through December 31, 2024.

Reflects the issuance of restricted shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from October 3, 2022 through December 31, 2024.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from January 11, 2023 through December 31, 2024.

Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with his services rendered as a director of the issuer from January 11, 2023 through December 31, 2024.

Reflects the issuance of restricted shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person.

On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.

Reflects the issuance of restricted shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person.

On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.

Reflects the grant of shares of the issuer's common stock in connection with the reporting person's appointment to the issuer's board of directors.

Reflects the issuance of shares of the issuer's common stock in connection with the issuer entering into a promissory note, dated December 27, 2024, with the reporting person.

Reflects the issuance of shares of the issuer's common stock in connection with the issuer entering into a promissory note, dated December 10, 2024, with the reporting person.

Reflects the issuance of shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person. The shares are subject to a one-year lock-up period ending on September 10, 2025.

Reflects the issuance of shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person. The shares are subject to a one-year lock-up period ending on September 10, 2025.

Reflects the issuance of shares of the issuer's common stock pursuant to a settlement agreement between the issuer and the reporting person, in consideration for unpaid, deferred wages owed to the reporting person. The shares are subject to a one-year lock-up period ending on September 10, 2025.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 360,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 270,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 45,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 6,705,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 90,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.

Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 360,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022.